1 Ocak 2019 Dergi makalesi Açık Erişim

Nayman, Ayse Hande; Siginc, Halime; Zemheri, Ebru; Yencilek, Faruk; Yildirim, Asif; Telci, Dilek

DataCite XML

<?xml version='1.0' encoding='utf-8'?>
<resource xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://datacite.org/schema/kernel-4" xsi:schemaLocation="http://datacite.org/schema/kernel-4 http://schema.datacite.org/meta/kernel-4.1/metadata.xsd">
  <identifier identifierType="URL">https://aperta.ulakbim.gov.tr/record/69817</identifier>
  <creators>
    <creator>
      <creatorName>Nayman, Ayse Hande</creatorName>
      <givenName>Ayse Hande</givenName>
      <familyName>Nayman</familyName>
      <affiliation>Yeditepe Univ, Fac Engn, Dept Genet &amp; Bioengn, Kayisdagi Cad, TR-34755 Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Siginc, Halime</creatorName>
      <givenName>Halime</givenName>
      <familyName>Siginc</familyName>
      <affiliation>Yeditepe Univ, Fac Engn, Dept Genet &amp; Bioengn, Kayisdagi Cad, TR-34755 Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Zemheri, Ebru</creatorName>
      <givenName>Ebru</givenName>
      <familyName>Zemheri</familyName>
      <affiliation>Umraniye Training &amp; Res Hosp, Dept Pathol, Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Yencilek, Faruk</creatorName>
      <givenName>Faruk</givenName>
      <familyName>Yencilek</familyName>
      <affiliation>Yeditepe Univ, Fac Sch Med, Yeditepe Univ Hosp, Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Yildirim, Asif</creatorName>
      <givenName>Asif</givenName>
      <familyName>Yildirim</familyName>
      <affiliation>Medeniyet Univ, Fac Med, Dept Urol, Istanbul, Turkey</affiliation>
    </creator>
    <creator>
      <creatorName>Telci, Dilek</creatorName>
      <givenName>Dilek</givenName>
      <familyName>Telci</familyName>
      <affiliation>Yeditepe Univ, Fac Engn, Dept Genet &amp; Bioengn, Kayisdagi Cad, TR-34755 Istanbul, Turkey</affiliation>
    </creator>
  </creators>
  <titles>
    <title>Dual-Inhibition Of Mtor And Bcl-2 Enhances The Anti-Tumor Effect Of Everolimus Against Renal Cell Carcinoma In Vitro And In Vivo</title>
  </titles>
  <publisher>Aperta</publisher>
  <publicationYear>2019</publicationYear>
  <dates>
    <date dateType="Issued">2019-01-01</date>
  </dates>
  <resourceType resourceTypeGeneral="Text">Journal article</resourceType>
  <alternateIdentifiers>
    <alternateIdentifier alternateIdentifierType="url">https://aperta.ulakbim.gov.tr/record/69817</alternateIdentifier>
  </alternateIdentifiers>
  <relatedIdentifiers>
    <relatedIdentifier relatedIdentifierType="DOI" relationType="IsIdenticalTo">10.7150/jca.29192</relatedIdentifier>
  </relatedIdentifiers>
  <rightsList>
    <rights rightsURI="http://www.opendefinition.org/licenses/cc-by">Creative Commons Attribution</rights>
    <rights rightsURI="info:eu-repo/semantics/openAccess">Open Access</rights>
  </rightsList>
  <descriptions>
    <description descriptionType="Abstract">Renal cell carcinoma (RCC) is the predominant type of kidney cancer. Mammalian target of rapamycin (mTOR) inhibitor everolimus is currently used as a second-line therapy for sorafenib or sunitinib-refractory metastatic RCC patients. The clinical limitation confronted during everolimus therapy is the onset of drug resistance that decreases the efficacy of the drug. Elevated level of anti-apoptotic Bcl-2 protein is proposed to be an emerging feedback loop for the acquired drug-resistance in various cancer types. In this study, the Bcl-2 inhibitor ABT-737 was used in combination with everolimus to enhance its anti-tumor effectiveness in everolimus-resistant RCC cell lines. Everolimus and ABT-737 combination synergistically led to a decrease in the proliferation of primary site A-498 and metastatic site Caki-1 RCC cell lines, which was accompanied by a reduction in protein levels of cell cycle and mTOR pathway proteins. In both RCC cell lines, everolimus-ABT-737 combination not only induced apoptosis, caspase and PARP-1 cleavage but also a decrease in Bcl-2 protein levels in parallel with a concomitant increase in Bim and Noxa levels.</description>
  </descriptions>
</resource>